Background Psoriasis has been shown to increase cardiovascular risk, and a contributor to this might be enhanced
Introduction
Psoriasis is a disease, in which T-cell activation and potent cytokine secretion lead to the stimulation and hyperproliferation of keratinocytes, rearrangement of dermal vasculature and innervation. [1] [2] [3] Psoriatic patients are predisposed to some pathological conditions, such as diabetes mellitus, lipoprotein disturbances and arterial hypertension, and have been evidenced to be at increased risk for cardiovascular morbidity and mortality [4] [5] [6] [7] [8] [9] [10] [11] and heart failure development. 12 Available data emerging from a few recent publications indicate that psoriatic patients are characterized by subclinical myocardial dysfunction as expressed by impaired left ventricular (LV) deformation (reflecting myocardial contractile properties) and diastolic indices, and abnormal left atrial mechanics. All these alterations occur independent of accompanying comorbidities, such as ischaemic heart disease, hypertension, diabetes mellitus, obesity or renal failure. 13, 14 Furthermore, the improvement in cardiac performance paralleling an amelioration in psoriasis severity achieved by biological therapy was demonstrated. 15 LV longitudinal deformation is a very sensitive measure of systolic function allowing for early detection of myocardial disease even in the preclinical stage. It reflects the contractility of subendocardial fibres, which are most vulnerable to the detrimental impact of pathological conditions, including myocardial fibrosis.
Galectin-3 (Gal-3) is a protein from a beta-galactoside-binding lectin family produced and released by activated macrophages, eosinophils and mast cells, as well as epithelial cells of skin, gastrointestinal and respiratory tracts. 16, 17 The biological effects of Gal-3 include promotion of cell adhesion and proliferationthe mechanisms being involved in the processes of fibrosis, tissue remodelling, cancer progression and immunological pathologies. Increased circulating Gal-3 was found in a number of disease states characterized by pro-inflammatory activation, e.g. obesity and heart failure. [18] [19] [20] [21] [22] [23] [24] Gal-3 expression in psoriatic skin is altered, with the absence of Gal-3 in the epidermis (unlike in the normal skin) and the Gal-3/ Gal-3-reactive glycoligands accumulation in the endothelial cells of dermal capillaries. These changes are presumed to be responsible for the abnormalities in the capillary system and migration of inflammatory cells to psoriatic skin. 25 In contrast to the aforementioned histopathologic findings, circulating Gal-3 profile has not been evaluated in the psoriatic population so far. We hypothesize that enhanced myocardial fibrosis promoted by the disease-attributable pro-inflammatory milieu might be a contributor to subclinical myocardial dysfunction in psoriatic patients, and Gal-3 upregulation may be a factor linking both pathologies.
Considering the important role of Gal-3 as a fibrosis-promoting factor, we sought to assess the serum concentration of Gal-3 and investigate the relationship of Gal-3 with inflammatory activation and LV systolic and diastolic function in patients with psoriasis.
Materials and methods
We prospectively enrolled 102 psoriatic patients (mean age: 52.5 AE 12.6 years), 54 men and 48 women, with the median duration of disease 10.0 (2.5-21.5) years, who were referred to the Department of Dermatology, Venereology and Allergology of Wroclaw Medical University Hospital from the network of local general practice. At enrolment, all patients were treated only with topical agents. In the pre-inclusion period of 6 months, no participant received systemic antipsoriatic treatments. None of enrolees was ever subjected to biological antipsoriatic therapy. Exclusion criteria encompassed any heart disease, hypertension, obesity, diabetes mellitus and other endocrine, renal, pulmonary and neoplastic diseases. Coronary artery disease was excluded on the basis of a negative history, normal resting ECG and the absence of wall motion abnormalities in echocardiography. The control group included 65 age-and sexmatched healthy volunteers. Subjects were informed regarding the purpose of the study and provided written informed consent. Investigations were in accordance with the Declaration of Helsinki and were approved by the local ethics committee.
Grading of the severity of psoriatic lesions was assessed by Psoriatic Arthritis Severity Index (PASI) including extent of skin involvement, severity of erythema, plaque thickness and the degree of scaling. 26 
Blood assays
Fasting peripheral venous blood samples were obtained between 08:00 and 09:00 h and immediately sent to the laboratory for standard measurement of glucose, insulin, HbA1c, creatinine, cholesterol, triglycerides, C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR); blood samples for serum Gal-3 estimation were frozen at À70°C until assayed. Gal-3 levels were quantified using ELISA kits (BioVendor Inc, Brno, Czech Republic). Intra-and interassay coefficients of variation were 6.3% and 8.7%, respectively.
Echocardiography
Echocardiographic imaging was performed using standard equipment (Vivid e9, General Electric Medical Systems, Milwaukee, WI) with a phased array 2.5 MHz multifrequency transducer. Offline analysis of images saved in raw data format was performed to assess the morphology and function of the heart. Cardiac dimensions, left ventricular peak early (E) and late diastolic flow velocity (A), deceleration time of early diastolic flow wave and peak early diastolic tissue velocity (e 0 ) at the septal and lateral portions of the mitral annulus were measured according to standard recommendations. 27, 28 Myocardial deformation was evaluated by a semi-automated 2D speckle tracking technique (Echopac PC version 113, GE Healthcare) from the three apical views with temporal resolution of 60-90 frames/s. After initial tracing of the endocardial border and subsequent software processing with myocardial segmentation and tracking of acoustic markers, segments that were not tracked satisfactorily were subjected to manual readjustment of the region of interest and if this was ineffective, they were excluded from the analysis. The greatest negative value on the strain curve during LV systole was measured, and averages from all analysable segments were presented as global longitudinal strain (GLS). All echocardiographic indices were averaged over three consecutive cardiac cycles.
Statistical analysis
Data are presented as mean AE SD for normally distributed variables, as median (interquartile range) for skewed variables (psoriasis duration, PASI score, Gal-3, HOMA IR [homoeostasis model of assessment-insulin resistance], ESR, CRP), and as counts and percentages for categorical variables. Between-group comparisons were performed by one-way analysis of variance with Scheffe's post hoc test for continuous variables and by chisquare for categorical variables. Associations between variables were evaluated by univariate and stepwise multiple regression analysis. To clarify the nature of the relationship between ESR and GLS, mediation analysis was employed, 29 using Gal-3 as a mediator variable. Skewed variables were log-transformed before being analysed. All calculations were carried out with standard statistical software (Statistica for Windows 13; StatSoft Inc., Tulsa, Oklahoma, USA). A P value of 0.05 was deemed to be statistically significant.
Results

Clinical characteristics
The demographic, clinical and echocardiographic data of the studied population are summarized in Table 1 . Significantly higher Gal-3 and markers of inflammatory activation (ESR and CRP) and reduced GLS were found in psoriatic patients. Patients and referents did not differ with respect to age, body fat indices, blood pressure, renal function, metabolic control, lipidogram and other than GLS echocardiographic parameters of cardiac morphology and function.
Galectin-3 tertiles
Psoriatic patients with serum Gal-3 within the third tertile demonstrated greater severity of the disease (as indicated by higher PASI) than their peers from the other two tertiles.
There was a progressive deterioration of GLS values across the Gal-3 tertiles. A trend was noted towards the decline in LV diastolic function with increasing Gal-3 (e 0 lateral in the third tertile significantly lower as compared to the first tertile; Table 2 ).
Interrelations
Univariate associations of GLS in patients with psoriasis are presented in Table 3 . Significant correlations between GLS and age, Gal-3, CRP, ESR, waist circumference and waist-to-hip ratio were found. The scatterplots illustrating associations among ESR, galectin-3 and GLS are presented in Fig. 1 .
Stepwise multiple regression analysis revealed that the independent determinants of GLS in psoriatic patients were Gal-3 and ESR (Table 4) . Other variables tested in the model included patient age, psoriasis duration, waist circumference, waist-to-hip ratio, blood pressure, eGFR, CRP and HOMA IR.
Regression-based mediation analysis demonstrated that the relationship between ESR and GLS was partially mediated by Gal-3, as evidenced by the reduction in variance of GLS explained by ESR after the inclusion of Gal-3 to the model (decrease in beta coefficient from À0.25 to À0.21; Fig. 2 ).
Discussion
The current study demonstrated that left ventricular longitudinal deformation is decreased in patients with psoriasis, and this subclinical systolic impairment is associated with immunological activation, with the increased Gal-3 acting as a mediator of this relationship. These findings suggest that proinflammatory upregulation in psoriasis may be responsible for the stimulation of myocardial fibrosis leading to LV functional derangements.
Cardiovascular disease in psoriasis
A growing body of evidence from epidemiologic and pathophysiologic studies indicates that psoriasis should be considered not only as one of the inflammatory skin disorders, but also as a systemic disease with increased incidence of the well-established factors of cardiovascular risk. The higher prevalence of the components of metabolic syndrome, such as obesity, impaired glucose metabolism, lipid disorders and hypertension or atherosclerosis in psoriatic patients, parallels greater cardiac morbidity and mortality in this population. [4] [5] [6] [7] [8] [9] The data obtained from the Danish cohort study show a 1.22-fold -1.57-fold higher prevalence of new-onset heart failure in mild and severe psoriasis in comparison with a non-psoriatic population. 12 This increase in heart failure risk can be attributable not solely to the atherosclerotic complications, but also to some psoriasis-related factors leading directly to the myocardial functional impairment. One of such links with well-known cardiodepressant properties is the pro-inflammatory activationa key pathophysiologic phenomenon in psoriasis. The current study revealed that patients with psoriasis were characterized by a significantly lower left ventricular GLS reflecting myocardial contractility than the group of healthy controls. Left ventricular systolic performance as expressed by GLS A, peak late diastolic mitral flow velocity; DT, deceleration time of early diastolic flow wave; E, peak early diastolic mitral flow velocity; e 0 , peak early diastolic mitral annular velocity; eGFR, estimated glomerular filtration rate; ESR, erythrocyte sedimentation rate; HbA1c, glycated hemoglobin; HDL, high-density lipoprotein; HOMA IR, homoeostasis model of assessment-insulin resistance; IVS, interventricular septal thickness; LDL, low-density lipoprotein; LV, left ventricular; PASI, Psoriasis Area Severity Index; PW, LV posterior wall thickness.
inversely correlated with simple laboratory markers of inflammation -CRP and ESR, and disease intensity represented by the PASI score. These findings are in line with the results of smaller studies reporting similar associations between left ventricular deformation indices (strain and strain rate) and hs-CRP13, as well as with a strong correlation between improvement in GLS and reduction in the PASI score achieved during a 3-month treatment with adalimumab or ustekinumab. 15 
Profibrotic activation and left ventricular impairment in psoriasis
A possible pathophysiological link between impaired myocardial performance and pro-inflammatory activation in psoriasis may include Gal-3 released by activated macrophages and fibroblasts. This lectin is considered to be a valuable marker of cardiac and vascular remodelling and fibrosis, capable of predicting incident heart failure, cardiovascular risk and all-cause mortality in general population. [30] [31] [32] [33] [34] [35] Gal-3 has been shown to accumulate in the immunologically infiltrated and fibrotically active regions of the diseased myocardium. 36 The profibrotic activity of Gal-3 includes stimulation of the proliferation and transformation of myocardial fibroblasts, with a subsequent increase in the formation and accumulation of collagen within the interstitium and perivascular space. 37 These changes may lead to left ventricular systolic and diastolic dysfunction, which is initially subclinical, but unless diagnosed and treated appropriately, it can progress in time to an overt heart failure. The present investigations showed an increased concentration of serum Gal-3 in psoriatic patients, as well as an inverse association between GLS and Gal-3, and a progressive deterioration of GLS across the Gal-3 tertiles, both of which might suggest a role for this lectin in the development of cardiac dysfunction in psoriasis. This notion has been further reinforced by the results of stepwise multiple regression analysis, which revealed that left ventricular longitudinal myocardial deformation in psoriatic patients was independently predicted by Gal-3 and ESR. The mediation analysis showed that the effect of ESR on GLS was in part mediated by Gal-3. This is consistent with the pathophysiological role of Gal-3, as well as with the recognized mechanisms promoting its release. Our findings are in line with a previously demonstrated relationship between depressed GLS and increased blood interleukin-6 in psoriatic patients. 38 Conversely, our work does not provide any clinical evidence supporting the postulated involvement of Gal-3 in the interleukin-6 and neutrophilmediated thrombotic mechanisms. Previous studies revealed the association between the duration of psoriasis or its severity, as assessed by the PASI score, and the degree of the left ventricular systolic impairment. 13, 15 The current investigation confirmed this relationship only with respect to the latter. It is likely that the PASI score more accurately reflects the activity of pathophysiological derangements responsible for the myocardial function abnormalities than the duration of the disease, which sometimes is difficult to precisely determine.
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Limitations
The present study has several limitations. First, we cannot clearly ascertain the absence of coronary artery disease in the study subjects, as neither coronary angiography nor noninvasive stress testing (exercise and/or pharmacological) was performed. Second, circulating Gal-3 is not exclusively specific for the heart and may also reflect extracardiac fibrosis. Third, the medications used by patients were not withdrawn before the investigations, which might have influenced the study results. Fourth, the cross-sectional observational nature of the present study precludes the ability to conclude about causal relations. Finally, as all the study participants were of Caucasian race, the applicability of our findings to other ethnic groups should be made with caution.
Conclusions
Subclinical left ventricular systolic dysfunction in psoriasis is linked with the inflammatory upregulation, and enhanced profibrotic activity (as reflected by elevated serum Gal-3) may be involved in this process. These putative mechanisms may be responsible for the observed higher incidence of heart failure in this disease condition and should be considered as a potential target for preventive and therapeutic measures.
